The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics
Open accessAbstract
While the unique metabolic activities of malignant tissues as potential targets for cancer therapeutics has been the subject of several recent reviews, the role of cholesterol metabolism in this context is yet to be fully explored. Cholesterol is an essential component of mammalian cell membranes as well as a precursor of bile acids and steroid hormones. The hypothesis that cancer cells need excess cholesterol and intermediates of the cholesterol biosynthesis pathway to maintain a high level of proliferation is well accepted, however the mechanisms by which malignant cells and tissues reprogram cholesterol synthesis, uptake and efflux are yet to be fully elucidated as potential therapeutic targets. High and low density plasma lipoproteins are the likely major suppliers of cholesterol to cancer cells and tumors, potentially via receptor mediated mechanisms. This review is primarily focused on the role(s) of lipoproteins in carcinogenesis, and their future roles as drug delivery vehicles for targeted cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
(2023) · doi:10.1126/science · Cited by 6,063
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
Simons, K., & Ikonen, E. (2000) · Science · doi:10.1126/science.290.5497.1721 · Cited by 1,275
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Zhuang, L., Kim, J., Adam, R. M., Solomon, K. R., & Freeman, M. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200519935 · Cited by 567 · cited 5×
“While statin therapy blocks the intracellular synthesis of cholesterol, it also alters the cholesterol content of tumor cell membranes, interfering with key signaling pathways (Zhuang et al., 2005).”
BackgroundInfluentialLi, Y. C., Park, M. J., Ye, S.-K., Kim, C.-W., & Kim, Y.-N. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050959 · Cited by 536
Dysregulation of the mevalonate pathway promotes transformation
Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910258107 · Cited by 417
Analysis of Cd44-Containing Lipid Rafts
Oliferenko, S., Paiha, K., Harder, T., Gerke, V., Schwärzler, C., Schwarz, H., Beug, H., Günthert, U., & Huber, L. A. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.843 · Cited by 405
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Thibault, A., Samid, D., Tompkins, A. C., Figg, W. D., Cooper, M. R., Hohl, R. J., Trepel, J. B., Liang, B., Patronas, N., Venzon, D. J., et al. (1996) · PubMed · Cited by 362
Mo, H., & Elson, C. E. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422900701 · Cited by 340
Self-citationLipoprotein-Inspired Nanoparticles for Cancer Theranostics
Ng, K. K., Lovell, J. F., & Zheng, G. (2011) · Accounts of Chemical Research · doi:10.1021/ar200017e · Cited by 330
Role of Cholesterol in the Development and Progression of Breast Cancer
Llaverias, G., Danilo, C., Mercier, I., Daumer, K., Capozza, F., Williams, T. M., Sotgia, F., Lisanti, M. P., & Frank, P. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2010.11.005 · Cited by 327
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.
Zhuang, L., Lin, J., Lu, M. L., Solomon, K. R., & Freeman, M. R. (2002) · PubMed · Cited by 327
Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells
Ho, Y., Smith, R., Brown, M., & Goldstein, J. (1978) · Blood · doi:10.1182/blood.v52.6.1099.1099 · Cited by 313
Cholesterol and prostate cancer
Pelton, K., Freeman, M. R., & Solomon, K. R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.006 · Cited by 303
Some new aspects of isoprenoid biosynthesis in plants—A review
Bach, T. J. (1995) · Lipids · doi:10.1007/bf02537822 · Cited by 303
(2019) · doi:10.1083/jcb · Cited by 257
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 239
Dillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Low-Density Lipoprotein as a Vehicle for Targeting Antitumor Compounds to Cancer Cells
Firestone, R. A. (1994) · Bioconjugate Chemistry · doi:10.1021/bc00026a002 · Cited by 225
Novel Aspects of Mevalonate Pathway Inhibitors as Antitumor Agents
Thurnher, M., Nussbaumer, O., & Gruenbacher, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0489 · Cited by 224
Shahzad, M. M. K., Mangala, L. S., Han, H. D., Lu, C., Bottsford-Miller, J., Nishimura, M., Mora, E. M., Lee, J.-W., Stone, R. L., Pecot, C. V., et al. (2011) · Neoplasia · doi:10.1593/neo.101372 · Cited by 221
Self-citationGajate, C., del Canto-Jañez, E., Acuña, A. U., Amat-Guerri, F., Geijo, E., Santos-Beneit, A. M., Veldman, R. J., & Mollinedo, F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040213 · Cited by 217
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting
Rensen, P. C. N., de Vrueh, R. L. A., Kuiper, J., Bijsterbosch, M. K., Biessen, E. A. L., & van Berkel, T. J. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00109-0 · Cited by 215
Li, H. Y., Appelbaum, F. R., Willman, C. L., Zager, R. A., & Banker, D. E. (2003) · Blood · doi:10.1182/blood-2002-07-2283 · Cited by 206
Pommier, A. J. C., Alves, G., Viennois, E., Bernard, S., Communal, Y., Sion, B., Marceau, G., Damon, C., Mouzat, K., Caira, F., et al. (2010) · Oncogene · doi:10.1038/onc.2010.30 · Cited by 206
Chen, X., & Resh, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208327200 · Cited by 202
Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation
Vitols, S., Gahrton, G., Ost, A., & Peterson, C. (1984) · Blood · doi:10.1182/blood.v63.5.1186.1186 · Cited by 170
Antalis, C. J., Uchida, A., Buhman, K. K., & Siddiqui, R. A. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-011-9405-9 · Cited by 165
Dietary cholesterol intake and cancer
Hu, J., La Vecchia, C., de Groh, M., Negri, E., Morrison, H., & Mery, L. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr155 · Cited by 163
Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target
Ginestier, C., Monville, F., Wicinski, J., Cabaud, O., Cervera, N., Josselin, E., Finetti, P., Guillé, A., Gaelle, L., Viens, P., et al. (2012) · Stem Cells · doi:10.1002/stem.1122 · Cited by 160
Song, J. H., Tse, M. C. L., Bellail, A., Phuphanich, S., Khuri, F., Kneteman, N. M., & Hao, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3896 · Cited by 160
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
The Role of Lipid Rafts in Cancer Cell Adhesion and Migration
Murai, T. (2011) · International Journal of Cell Biology · doi:10.1155/2012/763283 · Cited by 150
Cholesterol inhibition, cancer, and chemotherapy
Buchwald, H. (1992) · The Lancet · doi:10.1016/0140-6736(92)90744-n · Cited by 146
Cholesterol and breast cancer development
Danilo, C., & Frank, P. G. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.009 · Cited by 145
Mostaghel, E. A., Solomon, K. R., Pelton, K., Freeman, M. R., & Montgomery, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030062 · Cited by 137
Cholesterol Sensitivity of Endogenous and Myristoylated Akt
Adam, R. M., Mukhopadhyay, N. K., Kim, J., Vizio, D. D., Cinar, B., Boucher, K., Solomon, K. R., & Freeman, M. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0288 · Cited by 134
Vitols, S., Angelin, B., Ericsson, S., Gahrton, G., Juliusson, G., Masquelier, M., Paul, C., Peterson, C., Rudling, M. J., & Söderberg-Reid, K. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.7.2598 · Cited by 132
Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel
McConathy, W. J., Nair, M. P., Paranjape, S., Mooberry, L. K., & Lacko, A. G. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f1da86 · Cited by 119
Self-citationReceptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier
Mooberry, L. K., Nair, M. P., Paranjape, S., McConathy, W. J., & Lacko, A. G. (2009) · Journal of drug targeting · doi:10.3109/10611860903156419 · Cited by 117
Self-citationEzetimibe Is an Inhibitor of Tumor Angiogenesis
Solomon, K. R., Pelton, K., Boucher, K., Joo, J., Tully, C., Zurakowski, D., Schaffner, C. P., Kim, J., & Freeman, M. R. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080551 · Cited by 117
Duncan, R. E., El-Sohemy, A., & Archer, M. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400732200 · Cited by 113
Regulation of cholesterol biosynthesis and cancer signaling
Gorin, A. A., Gabitova, L., & Astsaturov, I. A. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.011 · Cited by 105
Lipid raft connection between extrinsic and intrinsic apoptotic pathways
Gajate, C., González‐Camacho, F., & Mollinedo, F. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.147 · Cited by 103
High density lipoprotein complexes as delivery vehicles for anticancer drugs.
Lacko, A. G., Nair, M. P., Paranjape, S., Johnso, S., & McConathy, W. J. (2002) · PubMed · Cited by 100
Self-citationNon-glucose metabolism in cancer cells—is it all in the fat?
Biswas, S., Lunec, J., & Bartlett, K. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9384-6 · Cited by 91
The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
Murtola, T. J., Syvälä, H., Pennanen, P. T., Bläuer, M., Solakivi, T., Ylikomi, T. J., & Tammela, T. L. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039445 · Cited by 90
Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs
Lacko, A. G., Nair, M. P., Prókai, L., & McConathy, W. J. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.6.665 · Cited by 88
Self-citationThe Complex Interplay Between Cholesterol and Prostate Malignancy
Solomon, K. R., & Freeman, M. R. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.04.001 · Cited by 88
Cholesterol metabolism and cancer: the good, the bad and the ugly
Silvente‐Poirot, S., & Poirot, M. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.10.004 · Cited by 87
Muntoni, S., Atzori, L., Mereu, R., Satta, G., Macis, M. D., Congia, M., Tedde, A., Desogus, A., & Muntoni, S. (2008) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.06.002 · Cited by 86
Cholesterol epoxide hydrolase and cancer
Silvente-Poirot, S., & Poirot, M. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.007 · Cited by 82
HMG-CoA reductase inhibitors: role in normal and malignant cells
Larsson, O. (1996) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(96)00193-x · Cited by 74
Krycer, J. R., Phan, L., & Brown, A. J. (2012) · Biochemical Journal · doi:10.1042/bj20120545 · Cited by 69
Insulin therapy in burn patients does not contribute to hepatic triglyceride production.
Aarsland, A. A., Chinkes, D. L., Sakurai, Y., Nguyen, T. T., Herndon, D. N., & Wolfe, R. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci200 · Cited by 66
Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines
Tatidis, L., Masquelier, M., & Vitols, S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01018-3 · Cited by 61
Oxysterol receptors, AKT and prostate cancer
Dufour, J., Viennois, É., de Boussac, H., Baron, S., & Lobaccaro, J. A. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.06.012 · Cited by 54
Drug Delivery Via lipoprotein-based Carriers: Answering the Challenges in Systemic Therapeutics
Sabnis, N. A., & Lacko, A. G. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.41 · Cited by 51
Self-citationOsDEG10 encoding a small RNA-binding protein is involved in abiotic stress signaling
Park, H.-Y., Kang, I. S., Han, J.-S., Lee, C.-H., An, G., & Moon, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.01.131 · Cited by 46
Native and modified lipoproteins as drug delivery systems
Bijsterbosch, M. K., & van Berkel, T. J. C. (1990) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(90)90018-n · Cited by 44
Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma
Sabnis, N. A., Pratap, S., Akopova, I., Bowman, P., & Lacko, A. G. (2013) · Frontiers in Pediatrics · doi:10.3389/fped.2013.00006 · Cited by 30
Self-citationYachnin, S., Toub, D. B., & Mannickarottu, V. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.3.894 · Cited by 29
Regulation of cholesterol metabolism in a slow-growing hepatoma in vivo
Erickson, S. K., Cooper, A. D., Barnard, G. F., Havel, C. M., Watson, J. A., Feingold, K. R., Moser, A. H., Hughes‐Fulford, M., & Siperstein, M. D. (1988) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(88)90058-6 · Cited by 23
Uda, S., Accossu, S., Spolitu, S., Collu, M., Angius, F., Sanna, F., Banni, S., Vacca, C., Murru, E., Mulas, C., et al. (2011) · Tumor Biology · doi:10.1007/s13277-011-0270-6 · Cited by 19
Yachnin, S., & Mannickarottu, V. (1984) · Blood · doi:10.1182/blood.v63.3.690.690 · Cited by 12
Kim, J., Vizio, D. D., Kim, T., Kim, J., Kim, M., Pelton, K., Clinton, S. K., Hai, T., Hwang, D., Solomon, K. R., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039448 · Cited by 11
Isoprenoids and Novel Inhibitors of Mevalonate Pathway Activities
Mo, H., & Elson, C. E. (2006) · Elsevier eBooks · doi:10.1016/b978-012088393-6/50094-4 · Cited by 8
Self-citationRole of the Mevalonate Pathway in Tocotrienol-Mediated Tumor Suppression
Elson, C. E., & Mo, H. (2008) · CRC Press eBooks · doi:10.1201/9781420080391.ch15 · Cited by 6
Self-citation(2014) · Institutional Repository University of Antioquia (University of Antioquia) · doi:10.1371/journal.pone
Cited by
Photodynamic therapy – mechanisms, photosensitizers and combinations
Kwiatkowski, S., Knap, B., Przystupski, D., Saczko, J., Kędzierska, E., Knap-Czop, K., Kotlińska, J., Michel, O., Kotowski, K., & Kulbacka, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.07.049 · Cited by 2,173
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
The Role of Cholesterol in Cancer
Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2613 · Cited by 708
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
The Multifaceted Biology of PCSK9
Seidah, N. G., & Prat, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab035 · Cited by 232
Metadata
- Authors
- Cruz, P. M. R., Mo, H., McConathy, W. J., Sabnis, N., & Lacko, A. G.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 4
- Pages
- 119-119
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2101375502
- Cited by
- 349
- References
- 77
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.